Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8517617 | Neuropharmacology | 2018 | 24 Pages |
Abstract
Despite Aβ or α-synuclein pathology in the current animal models, no difference was observed in the extent of drug transport across the BBB compared to wild type animals for any of the compounds investigated. Hence, the present study shows that the concept of a leaking barrier within neurodegenerative conditions has to be interpreted with caution when estimating drug transport into the brain. The capability of the highly dynamic BBB to regulate brain drug exposure still seems to be intact despite the presence of pathology.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Sofia Gustafsson, Veronica Lindström, Martin Ingelsson, Margareta Hammarlund-Udenaes, Stina Syvänen,